Patients with Deleterious Germline Variants in <i>STXBP2</i> Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel
Mark B. Leick(Massachusetts General Hospital), Marcela V. Maus(Center for Cancer Research), Hoyin Chu(Directorate-General for Interpretation), Grace Martin(Harvard University), Simone Filosto(Kite (United States)), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Bryan D. Choi(Harvard University), Michael C. Kann(Massachusetts General Hospital), Justin A. Budka(Gilead Sciences (United Kingdom)), Elba Gonzalez(Harvard University), Max Jan(Broad Institute), Christopher R. Reilly(Dana-Farber Cancer Institute), Tamina Kienka(Harvard University), Rebecca C. Larson(Harvard University), Harrison Silva(Massachusetts General Hospital), Nora Horick(Massachusetts General Hospital), Rhine R. Shen(Broad Institute), Charlotte Graham(Broad Institute), Stefanie R. Bailey(University of Virginia), Sabrina Y. Camp(Dana-Farber Cancer Institute), Riaz Gillani(Dana-Farber Cancer Institute), Saud H. AlDubayan(Broad Institute), Kathleen Gallagher(Massachusetts General Hospital), Seunghun Han(Chungbuk National University), Merle Phillips(Harvard University)
Cited by 3
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k